Regenxbio Inc (RGNX)
12.41
-0.67
(-5.12%)
USD |
NASDAQ |
Jun 14, 16:00
12.40
-0.01
(-0.08%)
After-Hours: 20:00
Regenxbio Accounts Receivable (Quarterly): 4.803M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 4.803M |
December 31, 2023 | 0.265M |
September 30, 2023 | 0.092M |
June 30, 2023 | 0.393M |
March 31, 2023 | 0.25M |
December 31, 2022 | 0.28M |
September 30, 2022 | 0.15M |
June 30, 2022 | 4.028M |
March 31, 2022 | 0.44M |
December 31, 2021 | 0.365M |
September 30, 2021 | 30.25M |
June 30, 2021 | 30.16M |
March 31, 2021 | 30.58M |
December 31, 2020 | 30.57M |
September 30, 2020 | 30.09M |
June 30, 2020 | 42.88M |
March 31, 2020 | 44.52M |
December 31, 2019 | 0.376M |
September 30, 2019 | 19.18M |
Date | Value |
---|---|
June 30, 2019 | 9.679M |
March 31, 2019 | 8.372M |
December 31, 2018 | 8.587M |
September 30, 2018 | 2.626M |
June 30, 2018 | 0.739M |
March 31, 2018 | 25.98M |
December 31, 2017 | 0.473M |
September 30, 2017 | 0.884M |
June 30, 2017 | 0.05M |
March 31, 2017 | 0.228M |
December 31, 2016 | 1.032M |
September 30, 2016 | 0.679M |
June 30, 2016 | 0.783M |
March 31, 2016 | 2.036M |
December 31, 2015 | 2.136M |
September 30, 2015 | 0.609M |
June 30, 2015 | 0.704M |
December 31, 2014 | 0.805M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
0.092M
Minimum
Sep 2023
44.52M
Maximum
Mar 2020
13.97M
Average
4.416M
Median
Accounts Receivable (Quarterly) Benchmarks
Pfizer Inc | 10.99B |
ACADIA Pharmaceuticals Inc | 94.70M |
Alnylam Pharmaceuticals Inc | 321.38M |
Catalyst Pharmaceuticals Inc | 60.49M |
Vertex Pharmaceuticals Inc | 1.793B |